News Related to Tenofovir Alafenamide

Related coverage linked through entity extraction aliases.

Merck's Two-Drug HIV Regimen Meets Primary Endpoint in Phase 3 Trial

Feb 27, 2026

Merck announced Phase 3 trial results for its investigational once-daily, two-drug HIV regimen doravirine/islatravir at CROI 2026, demonstrating non-inferiority to standard treatment in treatment-naïve adults with viral suppression rates of 91.8% at Week 48.

Single-Tablet HIV Regimen Combining Bictegravir and Lenacapavir Meets Phase 3 Trial Endpoints

Feb 26, 2026

A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.